|
WO2021044009A1
|
|
Herv inhibitors for use in treating tauopathies
|
|
WO2021008890A1
|
|
Nmda receptor constructs to detect and isolate nmdar autoantibodies
|
|
WO2020245343A1
|
|
Chimeric autoantibody receptor (caar) that binds autoantibodies targeting the central nervous system in neurological autoimmune disease
|
|
WO2020221937A1
|
|
Immunogen for preventing or treating familial frontotemporal dementia (ftd) and/or amyotrophic lateral sclerosis (als)
|
|
DE102017127865A1
|
|
Connection to the application in increasing mental performance
|
|
WO2018069312A1
|
|
Treatment of synucleinopathies
|
|
WO2018015573A2
|
|
Trem2 cleavage modulators and uses thereof
|
|
AU2016309738A1
|
|
Antibody or antibody fragment or non-Ig scaffold binding to a binding region of an anti-NMDARI-D-aspartate (NMDA) receptor antibody
|
|
US2017304241A1
|
|
Perk activator for the treatment of neurodegenerative diseases
|
|
EP3588091A1
|
|
Dipeptide-repeat proteins as therapeutic target in neurodegenerative diseases with hexanucleotide repeat expansion
|
